Keywords: astrazeneca, heart, drug, atacand, reduces, diabetes, risk
AstraZeneca's heart drug Atacand also reduces diabetes risk
Article | 12 September 2005
Anglo-Swedish drug major AstraZeneca's angiotensin II receptor blocker Atacand (candesartan cilexetil) has yielded good results from a prospectively-defined, secondary analysis ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
